Compare Inovio Pharmaceuticals Inc (INO) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Sony Group Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Sony Group Corp trades at $21.2 (market cap $125.96B). The key difference: Sony Group Corp is far larger — about 1411× Inovio Pharmaceuticals Inc's market cap, and Sony Group Corp pays a 0.75% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SONY | |
|---|---|---|
Market Cap | $89.27M | $125.96B |
Sector | Health | Technology |
52-Week High | $2.87 | $30.26 |
52-Week Low | $1.05 | $19.32 |
Enterprise Value | $60.28M | $122.45B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Sony trades at $21.165 with modest daily gains of 0.21%, supported by strong technical momentum and bullish analyst sentiment. The company demonstrates solid fundamentals with $12.96T in revenue and $1.14T net income for 2025, though recent Q1 2026 earnings missed expectations. Sony's entertainment strategy expansion and digital gaming transition position it for long-term growth despite near-term execution risks.
Sony presents a compelling investment case with strong cash flow generation and analyst support, though investors must monitor the digital gaming transition execution and potential revenue volatility. The stock's current valuation metrics appear reasonable given the company's market position and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
